Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: Implications for their use as immunization vectors

Human Gene Therapy

Volumn 18, Issue 2, 2007, Pages 93-105

  Santos, Kathlyn ^a   Simon, David A L ^a   Conway, Erin ^a   Bowers, William J ^a   Mitra, Soumya ^b   Foster, Thomas H ^a,b   Lugade, Amit ^a   Lord, Edith M ^a   Federoff, Howard J ^a   Dewhurst, Stephen ^a   Frelinger, John G ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; GENE PRODUCT; HERPES SIMPLEX VACCINE; LUCIFERASE; RECOMBINANT PROTEIN;

AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; ENZYME ASSAY; FEMALE; GENE CONSTRUCT; GENE SILENCING; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPORTER GENE; VIRUS EXPRESSION;

ANIMALS; ANTIGEN-PRESENTING CELLS; BIOPSY; CELL MOVEMENT; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 1, HUMAN; IMMUNIZATION; LUCIFERASES; MICE; MICE, INBRED BALB C; TIME FACTORS; TRANSDUCTION, GENETIC;

HERPES; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; MUS;

EID: 33947408025     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.082     Document Type: Article

References (68)

1. BANCHEREAU, J., and STEINMAN, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
2. BOWERS, W.J., HOWARD, D.F., and FEDEROFF, H.J. (2000). Discordance between expression and genome transfer titering of HSV amplicon vectors: Recommendation for standardized enumeration. Mol. Ther. 1, 294-299.
3. BOWERS, W.J., HOWARD, D.F., BROOKS, A.I., HALTERMAN, M.W., and FEDEROFF, H.J. (2001). Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers. Gene Ther. 8, 111-120.
4. BOWERS, W.J., MASTRANGELO, M.A., STANLEY, H.A., CASEY, A.E., MILO, L.J., Jr., and FEDEROFF, H.J. (2005). HSV amplicon-mediated Aβ vaccination in Tg2576 mice: Differential antigen-specific immune responses. Neurobiol. Aging 26, 393-407.
5. BOYER, J.L., KOBINGER, G., WILSON, J.M., and CRYSTAL, R.G. (2005). Adenovirus-based genetic vaccines for biodefense. Hum. Gene Ther. 16, 157-168.
6. CALEY, I.J., BETTS, M.R., DAVIS, N.L., SWANSTROM, R., FRELINGER, J.A., and JOHNSTON, R.E. (1999). Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins'. Vector design strategies for improved vaccine efficacy. Vaccine 17, 3124-3135.
7. CHEN, W., ANTON, L.C., BENNINK, J.R., and YEWDELL, J.W. (2000). Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12, 83-93.
8. CHEN, W.Y., BAILEY, E.C., McCUNE, S.L., DONG, J.Y., and TOWNES, T.M. (1997). Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 94, 5798-5803.
9. CHOY, G., CHOYKE, P., and LIBUTTI, S.K. (2003a). Current advances in molecular imaging: Noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol. Imaging 2, 303-312.
10. CHOY, G., O'CONNOR, S., DIEHN, F.E., COSTOUROS, N., ALEXANDER, H.R., CHOYKE, P., and LIBUTTI, S.K. (2003b). Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques 35, 1022-1026, 1028-1030.
11. CORISH, P., and TYLER-SMITH, C. (1999). Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng. 12, 1035-1040.
12. DA COSTA, X.J., JONES, C.A., and KNIPE, D.M. (1999). Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc. Natl. Acad. Sci. U.S.A. 96, 6994-6998.
13. DAY, R.N., KAWECKI, M., and BERRY, D. (1998). Dual-function reporter protein for analysis of gene expression in living cells. Biotechniques 25, 848-850, 852-844, 856.
14. + T cells: Cross-priming in infectious diseases. Curr. Opin. Immunol. 13, 437-441.
15. DETRAIT, E.R., BOWERS, W.J., HALTERMAN, M.W., GIULIANO, R.E., BENNICE, L., FEDEROFF, H.J., and RICHFIELD, E.K. (2002). Reporter gene transfer induces apoptosis in primary cortical neurons. Mol. Then 5, 723-730.
16. DUDEK, T., and KNIPE, D.M. (2006). Replication-defective viruses as vaccines and vaccine vectors. Virology 344, 230-239.
17. EPSTEIN, A.L. (2005). HSV-1-based amplicon vectors: Design and applications. Gene Ther. 12(Suppl. 1), S154-S158.
18. EPSTEIN, A.L., MARCONI, P., ARGNANI, R., and MANSERVIGI, R. (2005). HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr. Gene Ther. 5, 445-458.
19. FAN, S., MAGUIRE, C.A., RAMIREZ, S.H., BRADEL-TRETHEWAY, B., SAPINORO, R., SUI, Z., CHAKRABORTY-SETT, S., and DEWHURST, S. (2005). Valproic acid enhances gene expression from viral gene transfer vectors. J. Virol. Methods 125, 23-33.
20. GAETANO, C., CATALANO, A., PALUMBO, R., ILLI, B., ORLANDO, G., VENTORUZZO, G., SERINO, F., and CAPOGROSSI, M.C. (2000). Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Ther. 7, 1624-1630.
21. GELLER, A.I., and BREAKEFIELD, X.O. (1988). A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 241, 1667-1669.
22. GELLER, A.I., YU, L., WANG, Y., and FRAEFEL, C. (1997). Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Exp. Neurol. 144, 98-102.
23. GORANTLA, S., SANTOS, K., MEYER, V., DEWHURST, S., BOWERS, W.J., FEDEROFF, H.J., GENDELMAN, H.E., and POLUEKTOVA, L. (2005). Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J. Virol. 79, 2124-2132.
24. HEATH, W.R., and CARBONE, F.R. (2001). Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64.
25. HICKMAN-MILLER, H.D., and YEWDELL, J.W. (2006). Youth has its privileges: Maturation inhibits DC cross-priming. Nat. Immunol. 7, 125-126.
26. HOCKNELL, P.K., WILEY, R.D., WANG, X., EVANS, T.G., BOWERS, W.J., HANKE, T., FEDEROFF, H.J., and DEWHURST, S. (2002). Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J. Virol. 76, 5565-5580.
27. IGNOWSKI, J.M., and SCHAFFER, D.V. (2004). Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol. Bioeng. 86, 827-834.
28. JENKINS, M.K., KHORUTS, A., INGULLI, E., MUELLER, D.L., McSORLEY, S.J., REINHARDT, R.L., ITANO, A., and PAPE, K.A. (2001). In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 19, 23-45.
29. JIN, B.K., BELLONI, M., CONTI, B., FEDEROFF, H.J., STARR, R., SON, J.H., BAKER, H., and JOH, T.H. (1996). Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum. Gene Ther. 7, 2015-2024.
30. JONES, C.A., and KNIPE, D. (2003). Herpes simplex virus vaccines. Pediatr. Infect. Dis. J. 22, 1003-1005.
31. KAPLITT, M.G., KWONG, A.D., KLEOPOULOS, S.P., MOBBS, C.V., RABKIN, S.D., and PFAFF, D.W. (1994). Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc. Natl. Acad. Sci. U.S.A. 91, 8979-8983.
32. KAWAMURA, T., AZUMA, M., KAYAGAKI, N., SHIMADA, S., YAGITA, H., and OKUMURA, K. (1999). Fas/Fas ligand-mediated elimination of antigen-bearing Langerhans cells in draining lymph nodes. Br. J. Dermatol. 141, 201-205.
33. KAWAMURA, T., AZUMA, M., KAYAGAKI, N., SHIMADA, S., YAGITA, H., and OKUMURA, K. (2000). Fas/Fas ligand-mediated apoptosis of murine Langerhans cells. J. Dermatol. Sci. 22, 96-101.
34. KUTUBUDDIN, M., FEDEROFF, H.J., CHALLITA-EID, P.M., HALTERMAN, M., DAY, B., ATKINSON, M., FLANELLES, V., and ROSENBLATT, J.D. (1999). Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93, 643-654.
35. LARSEN, C.P., STEINMAN, R.M., WITMER-PACK, M., HANKINS, D.F., MORRIS, P.J., and AUSTYN, J.M. (1990). Migration and maturation of Langerhans cells in skin transplants and explants. J. Exp. Med. 172, 1483-1493.
36. LAUTERBACH, H., KERKSIEK, K.M., BUSCH, D.H., BERTO, E., BOZAC, A., MAVROMARA, P., MANSERVIGI, R., EPSTEIN, A.L., MARCONI, P., and BROCKER, T. (2004). Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J. Virol. 78, 4020-4028.
37. LUNDSTROM, K. (2003a). Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines 2, 447-459.
38. LUNDSTROM, K. (2003b). Semliki Forest virus vectors for gene therapy. Expert Opin. Biol. Ther. 3, 771-777.
39. LUNDSTROM, K. (2004). Gene therapy applications of viral vectors. Technol. Cancer Res. Treat. 3, 467-477.
40. MEDEMA, J.P., SCHUURHUIS, D.H., REA, D., VAN TONGEREN, J., DE JONG, J., BRES, S.A., LABAN, S., TOES, R.E., TOEBES, M., SCHUMACHER, T.N., BLADERGROEN, B.A., OSSENDORP, F., KUMMER, J.A., MELIEF, C.J., and OFFRINGA, R. (2001). Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: Differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194, 657-667.
41. MUELLER, S.N., JONES, C.M., SMITH, C.M., HEATH, W.R., and CARBONE, F.R. (2002). Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J. Exp. Med. 195, 651-656.
42. MURPHY, G.G., LUCAS, W.T., MEANS, R.E., CZAJAK, S., HALE, C.L., LIFSON, J.D., KAUR, A., JOHNSON, R.P., KNIPE, D.M., and DESROSIERS, R.C. (2000). Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol. 74, 7745-7754.
43. NOPORA, A., and BROCKER, T. (2002). Bcl-2 controls dendritic cell longevity in vivo. J. Immunol. 169, 3006-3014.
44. NORBURY, C.C., and SIGAL, L.J. (2003). Cross priming or direct priming: Is that really the question? Curr. Opin. Immunol. 15, 82-88.
45. NUNEZ, R., FRAEFEL, C., SUTER, M., NUNEZ-LIMAN, A., LIOU, H.C., and ACKERMAN, M. (2004). Assessment of a cellular vaccination approach consisting of crawling dendritic cells (CDCs) transduced with HSV-1-Δpac vectors. Immunol. Res. 30, 105-124.
46. OEHMIG, A., FRAEFEL, C., and BREAKEFIELD, X.O. (2004). Update on herpesvirus amplicon vectors. Mol. Ther. 10, 630-643.
47. OKABE, M., IKAWA, M., KOMINAMI, K., NAKANISHI, T., and NISHIMUNE, Y. (1997). "Green mice" as a source of ubiquitous green cells. FEBS Lett. 407, 313-319.
48. OSTBERG, J.R., KABINGU, E., and REPASKY, E.A. (2003). Thermal regulation of dendritic cell activation and migration from skin explants. Int. J. Hyperthermia 19, 520-533.
49. RONCHESE, F., and HERMANS, I.F. (2001). Killing of dendritic cells: A life cut short or a purposeful death? J. Exp. Med. 194, F23-F26.
50. SAEKI, Y., FRAEFEL, C., ICHIKAWA, T., BREAKEFIELD, X.O., and CHIOCCA, E.A. (2001). Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol. Ther. 3, 591-601.
51. SALIO, M., CELLA, M., SUTER, M., and LANZAVECCHIA, A. (1999). Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 29, 3245-3253.
52. SANTRA, S., SCHMITZ, J.E., KURODA, M.J., LIFTON, M.A., NICKERSON, C.E., LORD, C.I., PAL, R., FRANCHINI, G., and LETVIN, N.L. (2002). Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. J. Immunol. 168, 1847-1853.
53. SCHIJNS, V.E., and TANCERAS, A. (2005). Vaccine adjuvant technology: From theoretical mechanisms to practical approaches. Dev. Biol. (Basel) 121, 127-134.
54. SIGAL, L.J., and ROCK, K.L. (2000). Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J. Exp. Med. 192, 1143-1150.
55. SOUZA, A.P., HAUT, L., REYES-SANDOVAL, A., and PINTO, A.R. (2005). Recombinant viruses as vaccines against viral diseases. Braz. J. Med. Biol. Res. 38, 509-522.
56. SPAETE, R.R., and FRENKEL, N. (1982). The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector. Cell 30, 295-304.
57. STAVROPOULOS, T.A., and STRATHDEE, C.A. (1998). An enhanced packaging system for helper-dependent herpes simplex virus vectors. J. Virol. 72, 7137-7143.
58. SUN, M., KONG, L., WANG, X., HOLMES, C., GAO, Q., ZHANG, G.R., PFEILSCHIFTER, J., GOLDSTEIN, D.S., and GELLER, A.I. (2004). Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum. Gene Ther. 15, 1177-1196.
59. SUZUKI, M., KASAI, K., and SAEKI, Y. (2006). Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J. Virol. 80, 3293-3300.
60. TOLBA, K.A., BOWERS, W.J., HILCHEY, S.P., HALTERMAN, M.W., HOWARD, D.F., GIULIANO, R.E., FEDEROFF, H.J., and ROSENBLATT, J.D. (2001). Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 98, 287-295.
61. TSIEN, R.Y. (1998). The green fluorescent protein. Annu. Rev. Biochem. 67, 509-544.
62. WADE-MARTINS, R., SMITH, E.R., TYMINSKI, E., CHIOCCA, E.A., and SAEKI, Y. (2001). An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat. Biotechnol. 19, 1067-1070.
63. WANG, X., WILEY, R.D., EVANS, T.G., BOWERS, W.J., FEDEROFF, H.J., and DEWHURST, S. (2003). Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine 21, 2288-2297.
64. WILLIS, R.A., BOWERS, W.J., TURNER, M.J., FISHER, T.L., ABDUL-ALIM, C.S., HOWARD, D.F., FEDEROFF, H.J., LORD, E.M., and FRELINGER, J.G. (2001). Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum. Gene Ther. 12, 1867-1879.
65. WILSON, N.S., BEHRENS, G.M., LUNDIE, R.J., SMITH, C.M., WAITHMAN, J., YOUNG, L., FOREHAN, S.P., MOUNT, A., STEPTOE, R.J., SHORTMAN, K.D., DE KONING-WARD, T.F., BELZ, G.T., CARBONE, F.R., CRABB, B.S., HEATH, W.R., and VILLADANGOS, J.A. (2006). Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7, 165-172.
66. YANG, T., ZHANG, G.R., ZHANG, W., SUN, M., WANG, X., and GELLER, A.I. (2001). Enhanced reporter gene expression in the rat brain from helper virus-free HSV-1 vectors packaged in the presence of specific mutated HSV-1 proteins that affect the virion. Brain Res. Mol. Brain Res. 90, 1-16.
67. ZINKERNAGEL, R.M. (2002). Immunity, immunopathology and vaccines against HIV? Vaccine 20, 1913-1917.
68. ZINKERNAGEL, R.M., and HENGARTNER, H. (2004). On immunity against infections and vaccines: Credo 2004. Scand. J. Immunol. 60, 9-13.